Also, deals involving AbCellera/Angios, AstraZeneca/Alchemab, Kowa/Esteve, OSE/Veloxis, Tris/Park, Core One/Akome and Vertex/Obsidian.

In an interview, CEO Rob Armstrong said the company has created “a lot optionality” for how it can develop the programs it takes on from the big pharma’s portfolio management.

A year after COVID-19 first turned the world upside down, executives across the biopharma industry consider what 2021 holds in store. The impact of the pandemic will have profound and long-lasting implications for a sector that has been at the heart of responding to the global health challenge.

A strong year is predicted for biopharma business with investment and deal making set to continue apace. Executives across industry share their forecasts for the year ahead.